Abstract
Advanced hepatocellular carcinoma is the third most common cause of cancer-related mortality worldwide. Systemic therapy has historically had limited efficacy; however, targeted therapies offer promise in improving patient outcomes. Recently, two pivotal phase III randomized double-blind trials of the oral multi-tyrosine kinase inhibitor sorafenib compared with placebo demonstrated a survival benefit in advanced hepatocellular carcinoma. Other targeted agents have also shown promising results in early-phase trials. This review examines the current knowledge about targeted therapies in advanced hepatocellular carcinoma and addresses some of the key issues for future research in this disease.
| Original language | English |
|---|---|
| Pages (from-to) | 81-94 |
| Number of pages | 14 |
| Journal | Asia Pacific Journal of Oncology and Hematology |
| Volume | 2 |
| Issue number | 1 |
| Publication status | Published - Feb 2010 |
| Externally published | Yes |
Keywords
- Angiogenesis
- Growth factor
- Growth factor receptor
- Hepatocellular carcinoma
- Signal transduction pathways
- Sorafenib
- Targeted therapies